دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Phenotype and Natural History of Children With Coexistent Inflammatory Bowel Disease and Celiac Disease
Matteo Bramuzzo, MD, Paolo Lionetti, MD, PhD, Erasmo Miele, MD, PhD, Claudio Romano, MD, PhD, Serena Arrigo, MD, Sabrina Cardile, MD, Giovanni Di Nardo, MD, PhD, Maria Teresa Illiceto, MD, Maria Pastore, MD, Enrico Felici, MD, Maurizio Fuoti, MD, Claudia Banzato, MD, PhD, Michele Citrano, MD, Mauro Congia, MD, Lorenzo Norsa, MD, PhD, Elena Pozzi, MD, Giovanna Zuin, Anna Agrusti, MD, Martina Bianconi, MD, Claudia Grieco, MD, Fabiola Giudici, MHSc, Marina Aloi, MD, PhD, Patrizia Alvisi, MD SIGENP IBD Group
doi : 10.1093/ibd/izaa360
Inflammatory Bowel Diseases, Volume 27, Issue 12, December 2021, Pages 1881–1888
Adult patients with both inflammatory bowel disease (IBD) and celiac disease (CeD) have peculiar phenotypic features. This study aimed at describing the characteristics and natural history of children with both IBD and CeD.
Site- and Taxa-Specific Disease-Associated Oral Microbial Structures Distinguish Inflammatory Bowel Diseases
Hari K Somineni, PhD, Jordan H Weitzner, MD, Suresh Venkateswaran, PhD, Anne Dodd, Jarod Prince, Arjuna Karikaran, Cary G Sauer, MD, Shelly Abramowicz, DMD, MPH, Michael E Zwick, PhD, David J Cutler, PhD, David T Okou, PhD, Pankaj Chopra, PhD, Subra Kugathasan, MD
doi : 10.1093/ibd/izab082
Inflammatory Bowel Diseases, Volume 27, Issue 12, December 2021, Pages 1889–1900
The gut and oral microbiome have independently been shown to be associated with inflammatory bowel disease (IBD). However, it is not known to what extent gut and oral microbial disease markers converge in terms of their composition in IBD. Further, the spatial and temporal variation within the oral microenvironments of IBD remain to be elucidated.
Anti-TNF-? Treatment Reduces the Baseline Procoagulant Imbalance of Patients With Inflammatory Bowel Diseases
Armando Tripodi, PhD, Luisa Spina, MD, PhD, Laura Francesca Pisani, PhD, Lidia Padovan, PhD, Flaminia Cavallaro, MD, PhD, Veena Chantarangkul, PhD, Carla Valsecchi, PhD, Flora Peyvandi, MD, PhD, Maurizio Vecchi, MD
doi : 10.1093/ibd/izaa351
Inflammatory Bowel Diseases, Volume 27, Issue 12, December 2021, Pages 1901–1908
Inflammatory bowel diseases (IBD) are characterized by an increased thrombosis risk of uncertain etiology. Coagulation derangement arising from inflammation may be a triggering factor. We hypothesized that strong inflammation inhibitors (eg, anti-tumor necrosis factor-? drugs) may affect coagulation.
A Single Educational Intervention Improves Pregnancy-Related Knowledge and Emotional Health Among Women With IBD Who Are Pregnant or Wish to Conceive
Emma Flanagan, MBBS, FRACP, Emily K Wright, MBBS, PhD, FRACP, Miles P Sparrow, MBBS, FRACP, Gregory T Moore, MBBS, PhD, FRACP, William R Connell, MBBS, FRACP, MD, Peter De Cruz, MBBS, PhD, FRACP, Britt Christensen, MBBS, FRACP, MPH, Edward Shelton, MBBS, FRACP, Michael A Kamm, MBBS, PhD, FRCP, FRACP, Mark G Ward, MBBS, FRACP, MD, Damian Dowling, MBBS, FRACP, Steven Brown, MBBS, PhD, FRACP, Soleiman Kashkooli, MD, FRACP, Alexander J Thompson, MBBS, PhD, FRACP, Alyson L Ross, RN, Katerina V Kiburg, MPH, Sally J Bell, MBBS, MD, FRACP The PICCOLO Study Group
doi : 10.1093/ibd/izab021
Inflammatory Bowel Diseases, Volume 27, Issue 12, December 2021, Pages 1909–1918
There is considerable interest in improving the education and care of women with inflammatory bowel disease (IBD) to improve pregnancy outcomes. Despite increased awareness, not all women with IBD have access to pregnancy-related education and the quality of counseling is variable. We aimed to assess the effectiveness of a simple educational intervention for improving pregnancy-related knowledge and to evaluate the effect of education on patient outcomes including anxiety, depression, and quality of life in women with IBD.
Trajectories of Fatigue in Inflammatory Bowel Disease
Birte Klusmann, MSc, Joke Fleer, PhD, K Annika Tovote, PhD, Rinse K Weersma, MD, PhD, Hendrik M van Dullemen, MD, PhD, Gerard Dijkstra, MD, PhD, Maya J Schroevers, PhD
doi : 10.1093/ibd/izab007
Inflammatory Bowel Diseases, Volume 27, Issue 12, December 2021, Pages 1919–1930
Fatigue is one of the most frequently reported symptoms by patients with inflammatory bowel disease (IBD), both during active disease phases as well as during clinical remission. This study addressed whether different trajectories of fatigue over time can be identified among patients with IBD. Subsequently, we compared the demographic and clinical characteristics between trajectories.
Clinical Outcomes and Response Predictors of Vedolizumab Induction Treatment for Korean Patients With Inflammatory Bowel Diseases Who Failed Anti-TNF Therapy: A KASID Prospective Multicenter Cohort Study
Jeongseok Kim, MD, MSc, Hyuk Yoon, MD, PhD, Nayoung Kim, MSc, Kang-Moon Lee, MD, PhD, Sung-Ae Jung, MD, PhD, Chang Hwan Choi, MD, PhD, Eun Soo Kim, MD, PhD, Yunho Jung, MD, PhD, Chang Soo Eun, MD, PhD, Tae Oh Kim, MD, PhD, Sang-Bum Kang, MD, PhD, You Sun Kim, MD, PhD, Geom-Seog Seo, MD, PhD, Chang Kyun Lee, MD, PhD, Jong Pil Im, MD, PhD, Soo Jung Park, MD, PhD, Dong Il Park, MD, PhD, Byong Duk Ye, MD, PhD on behalf of the IBD Research Group of the Korean Association for the Study of Intestinal Diseases
doi : 10.1093/ibd/izaa361
Inflammatory Bowel Diseases, Volume 27, Issue 12, December 2021, Pages 1931–1941
We investigated the real-life effectiveness and safety of vedolizumab (VDZ) induction therapy among Korean patients with Crohn disease (CD) or ulcerative colitis (UC) for whom anti-tumor necrosis factor therapy previously failed.
International Perspectives on Management of Inflammatory Bowel Disease: Opinion Differences and Similarities Between Patients and Physicians From the IBD GAPPS Survey
David T Rubin, MD, Charles Sninsky, MD, Britta Siegmund, MD, Miquel Sans, MD, Ailsa Hart, PhD, Brian Bressler, MD, Yoram Bouhnik, PhD, Alessandro Armuzzi, PhD, Anita Afzali, MD
doi : 10.1093/ibd/izab006
Inflammatory Bowel Diseases, Volume 27, Issue 12, December 2021, Pages 1942–1953
Inflammatory bowel diseases (IBD), including Crohn disease (CD) and ulcerative colitis (UC), are complex disorders with multiple comorbidities. We conducted international patient and physician surveys to evaluate current experiences and perceptions of patients with CD or UC and physicians who treat IBD.
Outcome of Reverse Switching From CT-P13 to Originator Infliximab in Patients With Inflammatory Bowel Disease
Shaden Mahmmod, MD, Johannes P D Schultheiss, MD, Ad A van Bodegraven, MD, PhD, Gerard Dijkstra, MD, PhD, Lennard P L Gilissen, MD, PhD, Frank Hoentjen, MD, PhD, Maurice W M D Lutgens, MD, PhD, Nofel Mahmmod, MD, Andrea E van der Meulen–de Jong, MD, PhD, Lisa J T Smits, MD, Adriaan C I T L Tan, MD, PhD, Bas Oldenburg, MD, PhD, Herma H Fidder, MD, PhD
doi : 10.1093/ibd/izaa364
Inflammatory Bowel Diseases, Volume 27, Issue 12, December 2021, Pages 1954–1962
Patients suffering from inflammatory bowel diseases (IBD) and treated with originator infliximab are increasingly being switched to biosimilars. Some patients, however, are “reverse switched” to treatment with the originator. Here we assess the prevalence of reverse switching, including its indication and outcomes.
Colectomy Incidence Rates in Five-Year Data From the Observational Postmarketing Ulcerative Colitis Study of Originator Infliximab
Julián Panés, MD, PhD, James O Lindsay, PhD, Niels Teich, MD, Stefan Lindgren, MD, PhD, Jean-Frédéric Colombel, MD, Heather Ann Flynn, RN, Susan Huyck, DrPH, Ruji Yao, PhD, George Philip, MD, Walter Reinisch, MD
doi : 10.1093/ibd/izab026
Inflammatory Bowel Diseases, Volume 27, Issue 12, December 2021, Pages 1963–1967
This analysis of the Observational Postmarketing Ulcerative Colitis Study examined incidence rates of colectomy in patients with ulcerative colitis who received originator infliximab (IFX) or conventional therapies (ConvRx) as per their treating physician.
Novel Genetic Variant Predicts Surgical Recurrence Risk in Crohn’s Disease Patients
Ming-Hsi Wang, MD, PhD, Jessica J Friton, MA, Laura E Raffals, MD, Jonathan A Leighton, MD, Shabana F Pasha, MD, Michael F Picco, MD, Kelly Monroe, MSW, Billy D Nix, Rodney D Newberry, MD, William A Faubion, MD
doi : 10.1093/ibd/izaa362
Inflammatory Bowel Diseases, Volume 27, Issue 12, December 2021, Pages 1968–1974
We aimed to identify a model of clinical and genetic risk factors through hypothesis-free search across genome that can predict the surgical recurrence risk after the first abdominal surgery in CD patients.
Nonhypoalbuminemic Inflammatory Bowel Disease in Dogs as Disease Model
Juan Hernandez, DVM, PhD, Elodie Rouillé, DVM, Florian Chocteau, DVM, Marie Allard, Karine Haurogné, Florence Lezin, Julie M Hervé, DVM, PhD, Jean-Marie Bach, DVM, PhD, Jérôme Abadie, DVM, PhD, Blandine Lieubeau, PhD
doi : 10.1093/ibd/izab064
Inflammatory Bowel Diseases, Volume 27, Issue 12, December 2021, Pages 1975–1985
The incidence of inflammatory bowel disease (IBD) is increasing worldwide, emphasizing the need of relevant models, as dogs spontaneously affected by IBD may be, for better knowledge of the disease’s physiopathology.
Combination of Vedolizumab With Tacrolimus Is More Efficient Than Vedolizumab Alone in the Treatment of Experimental Colitis
Roberto Manzini, MSc, Marlene Schwarzfischer, MSc, Kirstin Atrott, Andrea Laimbacher, PhD, Silvia Lang, Marcin Wawrzyniak, PhD, Andreas Rickenbacher, MD, Matthias Turina, MD, Petr Hruz, PhD, Donata Lissner, PhD, Britta Siegmund, PhD, Gerhard Rogler, MD, PhD, Michael Scharl, MD, Marianne R Spalinger, PhD
doi : 10.1093/ibd/izab116
Inflammatory Bowel Diseases, Volume 27, Issue 12, December 2021, Pages 1986–1998
Vedolizumab is a widely used and safe therapy in inflammatory bowel disease, particularly in ulcerative colitis (UC), making it a promising candidate for enhanced efficacy by combining it with additional immunomodulatory medications. In this study, we studied the impact of vedolizumab monotreatment vs vedolizumab coadministration with other immunomodulatory drugs on intestinal inflammation and intestinal immune cells in vivo.
Randomized Controlled Trial Substudy of Cell-specific Mechanisms of Janus Kinase 1 Inhibition With Upadacitinib in the Crohn’s Disease Intestinal Mucosa: Analysis From the CELEST Study
Daniel Aguilar, PhD, Lluís Revilla, MS, Alba Garrido-Trigo, MS, Julian Panés, MD, PhD, Juan J Lozano, PhD, Núria Planell, PhD, Miriam Esteller, AAS, Ana P Lacerda, MD, Heath Guay, PhD, James Butler, MS, Justin Wade Davis, PhD, Azucena Salas, PhD
doi : 10.1093/ibd/izab116
Inflammatory Bowel Diseases, Volume 27, Issue 12, December 2021, Pages 1999–2009
Janus kinase (JAK) inhibition shows promise for treatment of patients with moderate to severe Crohn’s disease. We aimed to provide mechanistic insights into the JAK1-selective inhibitor upadacitinib through a transcriptomics substudy on biopsies from patients with Crohn's disease from CELEST.
Hit the Road JAK! The Role of New Oral Treatment in Inflammatory Bowel Disease
Isabel Garrido, MD, Susana Lopes, MD, PhD, Guilherme Macedo, MD, PhD
doi : 10.1093/ibd/izab037
Inflammatory Bowel Diseases, Volume 27, Issue 12, December 2021, Pages 2010–2022
Crohn disease (CD) and ulcerative colitis (UC) are considered chronic disorders of the gastrointestinal tract, lifelong medication often being necessary. Furthermore, they have significant implications on the quality of life. In the past few years, major advances have been achieved concerning the treatment of inflammatory bowel disease. These advances are expanding the possibilities for managing these patients. Janus kinase (JAK) inhibitors represent the most auspicious treatment to date because they consist of drugs that are orally administered, with a short half-life and low antigenicity. In addition, they seem to concurrently lessen various proinflammatory routes. In fact, tofacitinib has already been approved in patients with UC, both naïve and with prior exposure to tumor necrosis factor inhibitors. In CD, the results with tofacitinib have been less impressive. Several other JAK inhibitors are currently being investigated. However, given the wide spectrum of immunosuppressive effects, special attention has been given to the safety profile of these drugs, namely with regard to the occurrence of thromboembolic events, opportunistic infections, and malignancy. In this article, we review key evidence on the efficacy and safety of JAK inhibitors concerning both UC and CD.
Selective Tyrosine Kinase 2 Inhibition for Treatment of Inflammatory Bowel Disease: New Hope on the Rise
Silvio Danese, MD, PhD, Laurent Peyrin-Biroulet, MD, PhD
doi : 10.1093/ibd/izab135
Inflammatory Bowel Diseases, Volume 27, Issue 12, December 2021, Pages 2023–2030
Conventional systemic and biologic agents are the mainstay of inflammatory bowel disease (IBD) management; however, many of these agents are associated with loss of clinical response, highlighting the need for effective, novel targeted therapies. Janus kinase (JAK) 1-3 and tyrosine kinase 2 (TYK2) mediate signal transduction events downstream of multiple cytokine receptors that regulate targeted gene transcription, including the interleukin-12, interleukin-23, and type I interferon receptors for TYK2. This review summarizes the role of TYK2 signaling in IBD pathogenesis, the differential selectivity of TYK2 inhibitors, and the potential clinical implications of TYK2 inhibition in IBD. A PubMed literature review was conducted to identify studies of JAK1-3 and TYK2 inhibitors in IBD and other immune-mediated inflammatory diseases. Key efficacy and safety information was extracted and summarized. Pan-JAK inhibitors provide inconsistent efficacy in patients with IBD and are associated with toxicities resulting from a lack of selectivity at therapeutic dosages. Selective inhibition of TYK2 signaling via an allosteric mechanism, with an agent that binds to the regulatory (pseudokinase) domain, may reduce potential toxicities typically associated with JAK1-3 inhibitors. Deucravacitinib, a novel, oral, selective TYK2 inhibitor, and brepocitinib and PF-06826647, TYK2 inhibitors that bind to the active site in the catalytic domain, are in development for IBD and other immune-mediated inflammatory diseases. Allosteric TYK2 inhibition is more selective than JAK1-3 inhibition and has the potential to limit toxicities typically associated with JAK1-3 inhibitors. Future studies will be important in establishing the role of selective, allosteric TYK2 inhibition in the management of IBD.
Infliximab De-escalation in Patients With Crohn’s Disease in Clinical Remission Is Safe and Well-tolerated
Jessica R Allegretti, MD, Andrew Canakis, MD, Emma McClure, Jenna Marcus, Beth-Ann Norton, NP, Matthew J Hamilton, MD, Rachel W Winter, MD, Punyanganie S De Silva, MD, Sonia Friedman, MD, Joshua R Korzenik, MD
doi : 10.1093/ibd/izab131
Inflammatory Bowel Diseases, Volume 27, Issue 12, December 2021, Pages 2031–2033
Technical Issues Are a Major Determinant of Patient Satisfaction in Virtual Visits for Inflammatory Bowel Diseases
Afsoon Ghafari-Saravi, Shervin Rabizadeh, MD, MBA, Alan Dubovsky, MBA, Shaun Miller, MD, MBA, Gil Y Melmed, MD, MS, Welmoed K van Deen, MD, PhD
doi : 10.1093/ibd/izab121
Inflammatory Bowel Diseases, Volume 27, Issue 12, December 2021, Pages 2034–2037
Increased Bacterial Proteolytic Activity Detected Before Diagnosis of Ulcerative Colitis
Heather J Galipeau, PhD, Alberto Caminero, PhD, Elena F Verdu, MD, PhD
doi : 10.1093/ibd/izab144
Inflammatory Bowel Diseases, Volume 27, Issue 12, December 2021, Page e144
Autoimmune Enteropathy Presenting as Ascites in a Patient With Cirrhosis
Eman Hijab, Tanvi Dhere, MD
doi : 10.1093/ibd/izab149
Inflammatory Bowel Diseases, Volume 27, Issue 12, December 2021, Pages e145–e146
Use of Vedolizumab in Immune Checkpoint Inhibitor-associated Enterocolitis
Molly L Stone, MD, Erin M Forster, MD, MPH
doi : 10.1093/ibd/izab159
Inflammatory Bowel Diseases, Volume 27, Issue 12, December 2021, Page e147
A Case of Severe Vedolizumab-induced Liver Injury
Catherine Hsu, MBBChir, Rafid Sikafi, MBBS, MRCP, Claudia Moore-Gillon, MBBS, Robert Goldin, MD, MEd, FRCPath, Lucia Possamai, MBChB, MRCP, PhD
doi : 10.1093/ibd/izab160
Inflammatory Bowel Diseases, Volume 27, Issue 12, December 2021, Pages e148–e149
Safety and Efficacy of Ustekinumab for Ulcerative Colitis in a Liver Transplant Patient
Tomoyoshi Shibuya, MD, PhD, Osamu Nomura, MD, PhD, Akihito Nagahara, MD, PhD
doi : 10.1093/ibd/izab169
Inflammatory Bowel Diseases, Volume 27, Issue 12, December 2021, Pages e150–e151
Long-term Effects of Teduglutide on Intestinal Mucosa in a Patient With Crohn’s Disease and Short Bowel Syndrome: Clinical, Endoscopic and Histological Data Compared
Raffaele Borghini, MD, PhD, Vincenzo Villanacci, MD, Arianna Oberti, MD, Roberto Caronna, MD, Antonello Trecca, MD, PhD
doi : 10.1093/ibd/izab171
Inflammatory Bowel Diseases, Volume 27, Issue 12, December 2021, Pages e152–e153
Cytomegalovirus Limited to the Rectum in an Immunosuppressed IBD Patient
Lior Dar Antaki, MD, Alexander Volkov, MD, Shomron Ben-Horin, MD
doi : 10.1093/ibd/izab173
Inflammatory Bowel Diseases, Volume 27, Issue 12, December 2021, Pages e154–e155
Anti-TNF Therapy and the Risk of Herpes Zoster Among Patients With Inflammatory Bowel Disease
Cong Dai, PhD, Min Jiang, PhD, Yu-hong Huang, PhD
doi : 10.1093/ibd/izab178
Inflammatory Bowel Diseases, Volume 27, Issue 12, December 2021, Page e156
Success of Cyclosporin and Tofacitinib Combination Therapy in a Patient With Severe Steroid-refractory Ulcerative Colitis
Qinglu Yang, MD, Liang Chen, MD, PhD, Lijin Feng, MD, Changqin Liu, MD, Leilei Fang, MD, PhD, Zhanju Liu, MD, PhD, Xiaomin Sun, MD, PhD
doi : 10.1093/ibd/izab181
Inflammatory Bowel Diseases, Volume 27, Issue 12, December 2021, Pages e157–e158
Corticosteroids Can Be Used to Decrease Antidrug Antibodies in Pediatric Patients With Inflammatory Bowel Disease
Alexandra Falsey, MD, Diana Jo, MD, Helina Sirak, BA, Diana Moya, MD, Ian H Leibowitz, MD, Jane Yang, MD, Suchitra K Hourigan, MD, Eve May, MD
doi : 10.1093/ibd/izab182
Inflammatory Bowel Diseases, Volume 27, Issue 12, December 2021, Pages e159–e160
Unexpected Liver Lesions in Crohn’s Disease
Jian Tang, MD, Zicheng Huang, MD, Huili Guo, MD, Kang Chao, MD, Xiang Gao, MD
doi : 10.1093/ibd/izab186
Inflammatory Bowel Diseases, Volume 27, Issue 12, December 2021, Pages e161–e162
